MétaCan
Menu
← Back to cohort
Record W4415595419 · doi:10.1016/j.annonc.2025.10.1236

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer

2025· article· en· W4415595419 on OpenAlexafffund
Tuomo Virtanen, Edmond M. Kwan, Kinnari Parekh, Jack V. W. Bacon, Chia-Chi Flora Huang, Ivan Pak Lok Yu, Lauri Ryyppö, C. Bernales, Gráinne Donnellan, Constantine S. Tam, Joonatan Sipola, Jussi Nikkola, Gillian Vandekerkhove, Sofie H. Tolmeijer, Konsta Kukkonen, Adelia, Bernhard J. Eigl, Daygen L. Finch, R Gagnon, Y Takieldeen, E Hardy, Daniel Khalaf, Christian Kollmannsberger, Jean‐Michel Lavoie, Corinne Maurice‐Dror, S. Miller, Lucia Nappi, Krista Noonan, Sunil Parimi, Anna Riminchan, E Sartori-Mueller, Mohammad Soleimani, Joanna Vergidis, Muhammad Zulfiqar, Aaron R. Hansen, Sebastién J. Hotte, Mariam Jafri, Michael Kolinsky, Som D. Mukherjee, Michael Ong, April A. N. Rose, Wei Tu, E. Winquist, Andries M. Bergman, Kim van der Zande, Wilbert Zwart, Niven Mehra, Nielka P. van Erp, Jimmy L. Zhao, D. Rathkopf, Christopher E. Barbieri, David A. Quigley, Matti Nykter, Nathan A. Lack, K.N. Chi, Matti Annala, Alexander W. Wyatt

Bibliographic record

VenueAnnals of Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsOntario Institute for Cancer ResearchMcMaster UniversityQueen's UniversityHamilton Health SciencesOccupational Cancer Research CentreOttawa HospitalHealth Sciences CentreUniversity Health NetworkAbbotsford Veterinary ClinicJewish General HospitalSunnybrook Health Science CentreSurrey Place CentreJuravinski Cancer CentreCanadian Centre for Applied Research in Cancer ControlPrincess Margaret Cancer CentreLondon Health Sciences CentreInterior HealthBC Cancer AgencyUniversity of British Columbia
FundersCanadian Cancer Society Research InstituteCanadian Institutes of Health ResearchGenentechBC Cancer FoundationIpsenSyöpäsäätiöRadboud Universitair Medisch CentrumAstellas PharmaInstitute of Cancer ResearchTerry Fox Research InstituteMichael Smith Health Research BCSuomen KulttuurirahastoAcademy of FinlandEisaiEMD SeronoJane ja Aatos Erkon SäätiöRadboud UniversiteitCanadian Cancer SocietyPfizerAstraZenecaEli Lilly and CompanyBristol-Myers SquibbProstate Cancer Foundation
KeywordsRepertoireProstate cancerLocus (genetics)Somatic cellHierarchyClinical significance

Abstract

fetched live from OpenAlex

BACKGROUND: Somatic alterations to the androgen receptor (AR) gene are pivotal drivers of treatment resistance in metastatic castration-resistant prostate cancer (mCRPC), but their prevalence, clinical impact, and etiology remain incompletely understood. PATIENTS AND METHODS: We assembled a meta-cohort of 3048 plasma cell-free DNA and matched leukocyte DNA samples from 1751 mCRPC patients, accrued from eight clinical trials and a regional biobank. Samples were sequenced with successive generations of a custom targeted hybridization capture panel with extensive coverage of the AR locus and 71 prostate cancer genes, enabling comprehensive characterization of AR genotypes including enhancer and gene copy number amplification, and mutations or structural rearrangements. RESULTS: Somatic AR alterations, detected in 84% of mCRPC, were shaped by underlying genomics, including TP53 and DNA repair defects. Wnt-mutant tumors showed unique AR amplification structures characterized by preferential incorporation of an alternative downstream enhancer and low copy number. AR mutations were present in 19.7% of mCRPC, often subclonal, and enriched in tumors with AR enhancer-only gain. We establish a functional hierarchy of AR genotypes based on treatment responses and identify a specific class of AR rearrangements truncating the ligand-binding domain within intron 4 or exon 4 (ALTR4) that are under robust positive selection and strongly impact AR pathway inhibitor outcomes, distinct from other rearrangements arising as byproducts of AR amplification. We provide evidence that a subset of AR amplifications arise through breakage-fusion-bridge cycles with associated Xq loss. Some 16% of mCRPC lacked detectable AR alterations and had reduced frequency of ETS gene fusions, with many demonstrating robust responses to AR pathway inhibitors. CONCLUSIONS: This study provides the most comprehensive resource to date characterizing somatic alterations at the AR locus. Our clinicogenomic analysis establishes the repertoire and clinical relevance of AR genotypes in mCRPC, informing efforts to target renewed AR dependency.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.115
GPT teacher head0.504
Teacher spread0.389 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueAnnals of Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→